Erin Harris, chief editor of cellandgene.com explains what makes cell and gene therapy manufacturing more complex what some of the current hurdles and bottlenecks are that companies in this sector of life sciences face.
Newsletter Signup
This website uses cookies to ensure you get the best experience on our website. Learn more